Rabeprazole is a proton pump inhibitor used to help gastrointestinal ulcers heal, to treat symptoms of gastroesophageal reflux disease (GERD), to eradicate Helicobacter pylori, and to treat hypersecretory conditions such as Zollinger-Ellison Syndrome. Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.
- Mechanism
- Curator reviewed
Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.
- Primary indication
- For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.Curator reviewed · 13 structured indications
- Formula / weight
- C18H21N3O3S · 359.443 g/mol (avg)
- First approval
- Canada, 2001 · United States, 1999
- Code names
- E3810 · LY-307640
- Brand names
Resolves to
YREYEVIYCVEVJK-UHFFFAOYSA-NSMILESCOCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Rabeprazole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account